313 related articles for article (PubMed ID: 16019565)
21. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
[No Abstract] [Full Text] [Related]
22. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
23. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
[TBL] [Abstract][Full Text] [Related]
24. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
25. Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.
Preisinger C; Schwarz JP; Bleijerveld OB; Corradini E; Müller PJ; Anderson KI; Kolch W; Scholten A; Heck AJ
Leukemia; 2013 Mar; 27(3):743-6. PubMed ID: 22976128
[No Abstract] [Full Text] [Related]
26. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Liu NS; O'Brien S
Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
[TBL] [Abstract][Full Text] [Related]
27. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
[TBL] [Abstract][Full Text] [Related]
28. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
29. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
30. Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Mori T; Yamazaki R; Ikeda Y; Okamoto S
Br J Haematol; 2003 May; 121(4):533. PubMed ID: 12752093
[No Abstract] [Full Text] [Related]
31. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
32. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
34. Pathobiology of lymphoid and myeloid blast crisis and management issues.
Ilaria RL
Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
[TBL] [Abstract][Full Text] [Related]
35. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
Jørgensen HG; Copland M; Allan EK; Jiang X; Eaves A; Eaves C; Holyoake TL
Clin Cancer Res; 2006 Jan; 12(2):626-33. PubMed ID: 16428509
[TBL] [Abstract][Full Text] [Related]
36. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
37. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J
Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491
[No Abstract] [Full Text] [Related]
38. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
[TBL] [Abstract][Full Text] [Related]
39. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
40. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Mattison R; Larson RA
Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
